- Home
- HCM vs MRUS Comparison
HCM vs MRUS Comparison
Compare HCM & MRUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HCM
- MRUS
- Stock Information
- Founded
- HCM 2000
- MRUS 2003
- Country
- HCM Hong Kong
- MRUS Netherlands
- Employees
- HCM N/A
- MRUS N/A
- Industry
- HCM Biotechnology: Pharmaceutical Preparations
- MRUS Biotechnology: Pharmaceutical Preparations
- Sector
- HCM Health Care
- MRUS Health Care
- Exchange
- HCM Nasdaq
- MRUS Nasdaq
- Market Cap
- HCM 2.6B
- MRUS 2.9B
- IPO Year
- HCM N/A
- MRUS 2016
- Fundamental
- Price
- HCM $14.20
- MRUS $39.45
- Analyst Decision
- HCM Hold
- MRUS Strong Buy
- Analyst Count
- HCM 1
- MRUS 12
- Target Price
- HCM $19.00
- MRUS $87.92
- AVG Volume (30 Days)
- HCM 76.1K
- MRUS 718.6K
- Earning Date
- HCM 02-26-2025
- MRUS 02-26-2025
- Dividend Yield
- HCM N/A
- MRUS N/A
- EPS Growth
- HCM N/A
- MRUS N/A
- EPS
- HCM N/A
- MRUS N/A
- Revenue
- HCM $610,806,000.00
- MRUS $35,932,000.00
- Revenue This Year
- HCM N/A
- MRUS N/A
- Revenue Next Year
- HCM $20.69
- MRUS $57.37
- P/E Ratio
- HCM N/A
- MRUS N/A
- Revenue Growth
- HCM N/A
- MRUS N/A
- 52 Week Low
- HCM $11.93
- MRUS $31.62
- 52 Week High
- HCM $21.92
- MRUS $61.61
- Technical
- Relative Strength Index (RSI)
- HCM 42.32
- MRUS 38.07
- Support Level
- HCM $13.00
- MRUS $38.52
- Resistance Level
- HCM $15.29
- MRUS $47.75
- Average True Range (ATR)
- HCM 0.46
- MRUS 2.05
- MACD
- HCM -0.00
- MRUS -0.17
- Stochastic Oscillator
- HCM 37.74
- MRUS 16.83
About HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is an innovative biopharmaceutical company engaged in the discovery, global development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.
About MRUS Merus N.V.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.